The global pulmonary fibrosis biomarkers market is experiencing significant growth, driven by the increasing prevalence of pulmonary fibrosis and advancements in biomarker discovery technologies. In 2023, the market was valued at approximately USD 4.1 billion and is projected to surpass USD 6 billion by 2032, reflecting a compound annual growth rate (CAGR) of around 4.3% during the fo... https://www.analystviewmarketinsights.com/reports/report-highlight-pulmonary-fibrosis-biomarkers-market